← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Novavax, Inc. (NVAX) 10-Year Financial Performance & Capital Metrics

NVAX •
HealthcareBiotechnologyVaccines and Infectious Disease
AboutNovavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Show more
  • Revenue $1.12B +64.7%
  • EBITDA $453M +325.9%
  • Net Income $440M +334.8%
  • EPS (Diluted) 2.58 +309.8%
  • Gross Margin 93.5% +33.0%
  • EBITDA Margin 40.3% +237.2%
  • Operating Margin 40.3% +210.4%
  • Net Margin 39.19% +242.6%
  • ROE -
  • ROIC -
  • Debt/Equity -
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 87 (top 13%)
  • ✓Strong 5Y sales CAGR of 118.8%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 13.7% in last year

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y40.97%
5Y118.83%
3Y-11.1%
TTM64.69%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM334.83%

EPS CAGR

10Y-
5Y-
3Y-
TTM293.99%

ROCE

10Y Avg-113.88%
5Y Avg-159.88%
3Y Avg-118.62%
Latest80.67%

Peer Comparison

Vaccines and Infectious Disease
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CVACCureVac N.V.1.05B4.666.478.96%37.93%33.02%7.95%0.06
NVAXNovavax, Inc.1.67B10.143.9364.69%39.19%
SCNIScinai Immunotherapeutics Ltd.3.03B0.890.15401.83%58.65%0.21
TNXPTonix Pharmaceuticals Holding Corp.142.05M13.97-0.0829.94%-9.63%-42.93%0.04
INOInovio Pharmaceuticals, Inc.65.34M1.81-0.46-73.83%-592.82%-115.42%0.17
IVVDInvivyd, Inc.362.35M1.69-1.18-119.63%-64.32%0.02
SPROSpero Therapeutics, Inc.122.2M2.17-1.71-53.77%-122.56%-165.46%0.09
AVIRAtea Pharmaceuticals, Inc.365.63M4.68-2.34-46.56%0.00

Compare NVAX vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs BNTX

Compare head-to-head with BioNTech SE

vs MRNA

Compare head-to-head with Moderna, Inc.

Compare Top 5

vs BNTX, MRNA, SMMT, PCVX

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+15.35M31.18M34.29M18.66M22.39M197.58M1.6B556.38M682.16M1.12B
Revenue Growth %-57.65%103.06%9.98%-45.57%19.97%782.53%709.26%-65.2%22.61%64.69%
Cost of Goods Sold+237.94M00113.84M00902.64M343.77M202.74M73.04M
COGS % of Revenue1549.79%--610.02%--56.45%61.79%29.72%6.5%
Gross Profit+-222.59M31.18M34.29M-95.18M22.39M197.58M696.31M212.61M479.42M1.05B
Gross Margin %-1449.79%100%100%-510.02%100%100%43.55%38.21%70.28%93.5%
Gross Profit Growth %-76.1%114.01%9.98%-377.59%123.52%782.53%252.42%-69.47%125.49%119.1%
Operating Expenses+284.47M202.89M208.21M148.26M439.11M1.88B1.34B779.13M728.35M499.8M
OpEx % of Revenue1852.84%650.78%607.23%794.44%1961.35%953.61%83.87%140.03%106.77%44.49%
Selling, General & Admin46.53M34.45M34.41M34.42M145.29M298.36M488.69M468.95M337.19M157.48M
SG&A % of Revenue303.05%110.5%100.35%184.42%648.96%151.01%30.56%84.28%49.43%14.02%
Research & Development237.94M168.44M173.8M113.84M747.03M2.53B1.24B737.5M391.17M342.32M
R&D % of Revenue1549.79%540.27%506.87%610.02%3336.73%1282.77%77.26%132.55%57.34%30.47%
Other Operating Expenses-31K67K108K-13K-453.21M-948.71M-382.92M-427.32M00
Operating Income+-269.11M-171.71M-173.92M-120.58M-416.72M-1.69B-644.74M-566.51M-248.93M452.8M
Operating Margin %-1752.84%-550.78%-507.23%-646.13%-1861.35%-853.61%-40.32%-101.82%-36.49%40.3%
Operating Income Growth %-71.15%36.19%-1.29%30.67%-245.59%-304.73%61.77%12.13%56.06%281.9%
EBITDA+-260.61M-161.89M-165.76M-114.78M-411.83M-1.67B-615.68M-525.29M-200.44M452.8M
EBITDA Margin %-1697.44%-519.29%-483.43%-615.05%-1839.53%-847.2%-38.51%-94.41%-29.38%40.3%
EBITDA Growth %-72.3%37.88%-2.39%30.75%-258.8%-306.45%63.22%14.68%61.84%325.91%
D&A (Non-Cash Add-back)8.51M9.82M8.16M5.8M4.88M12.66M29.05M41.23M48.5M0
EBIT-267M-169.7M-172.56M-119.08M-403.11M-1.69B-633.77M-528.62M-156.54M0
Net Interest Income+-12.96M-14.07M-13.61M-12.1M-15.14M-21.13M-19.88M-14.42M-20.07M0
Interest Income0001.51M000000
Interest Expense12.96M14.07M12.19M13.61M15.14M21.13M19.88M14.42M20.07M-22.55M
Other Income/Expense-10.85M-12.06M-10.83M-12.11M-1.54M-27.96M-8.91M23.48M72.32M-10.63M
Pretax Income+-279.97M-183.77M-184.75M-132.69M-418.26M-1.71B-653.65M-543.03M-176.62M442.17M
Pretax Margin %-1823.53%-589.46%-538.81%-711.04%-1868.23%-867.76%-40.88%-97.6%-25.89%39.36%
Income Tax+2.32M01.36M0029.21M4.29M2.03M10.88M-1.86M
Effective Tax Rate %100%100%100%98.05%100%101.7%100.66%100.37%106.16%99.58%
Net Income+-279.97M-183.77M-184.75M-130.1M-418.26M-1.74B-657.94M-545.06M-187.5M440.3M
Net Margin %-1823.53%-589.46%-538.81%-697.15%-1868.23%-882.55%-41.15%-97.97%-27.49%39.19%
Net Income Growth %-78.39%34.36%-0.53%29.58%-221.49%-316.91%62.27%17.16%65.6%334.83%
Net Income (Continuing)-279.97M-183.77M-184.75M-132.69M-418.26M-1.74B-657.94M-545.06M-187.5M440.3M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-20.68-12.56-9.99-5.40-7.43-23.44-8.42-5.41-1.232.58
EPS Growth %-72.77%39.27%20.46%45.95%-37.59%-215.48%64.08%35.75%77.26%309.76%
EPS (Basic)-20.68-12.56-9.99-5.40-7.43-23.44-8.42-5.41-1.232.72
Diluted Shares Outstanding13.54M14.63M18.49M24.1M57.55M74.4M78.18M100.77M152.19M173.1M
Basic Shares Outstanding13.54M14.63M18.49M24.1M57.55M74.4M78.18M100.77M152.19M161.99M
Dividend Payout Ratio----------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+287.83M203.31M119.28M97.25M1.25B2.16B1.7B1.14B1.13B978.28M
Cash & Short-Term Investments144.35M106.31M70.15M78.82M711.05M1.52B1.34B568.5M923.12M735.08M
Cash Only144.35M106.31M70.15M78.82M553.4M1.52B1.34B568.5M530.23M240.63M
Short-Term Investments0000157.65M000392.89M494.45M
Accounts Receivable233K007.5M262.01M454.99M82.38M297.24M108.28M106.45M
Days Sales Outstanding5.54--146.694.27K840.5318.819557.9434.58
Inventory15.74M13.09M11.97M00036.68M41.7M8.75M11.54M
Days Inventory Outstanding24.14-----14.8344.2715.7557.69
Other Current Assets20.65M19.84M3.19M7.32M103.54M56.11M86.68M166.15M32.51M125.2M
Total Non-Current Assets+106.47M99.18M88.7M75.71M334.28M421.63M555.29M653.6M431.48M198.24M
Property, Plant & Equipment40.18M35.99M28.43M11.45M179.95M228.7M400.49M490.99M300M67.7M
Fixed Asset Turnover0.38x0.87x1.21x1.63x0.12x0.86x3.99x1.13x2.27x16.60x
Goodwill51.67M53.56M51.97M51.15M135.38M131.48M126.33M127.45M107.48M113.46M
Intangible Assets9.22M7.87M6.54M5.58M5.72M4.77M0000
Long-Term Investments4.59M890K958K410K01.65M1.66M000
Other Non-Current Assets5.39M1.76M1.77M7.53M13.22M56.69M28.47M35.16M24M17.08M
Total Assets+394.3M302.49M207.98M172.96M1.58B2.58B2.26B1.8B1.56B1.18B
Asset Turnover0.04x0.10x0.16x0.11x0.01x0.08x0.71x0.31x0.44x0.95x
Asset Growth %2.14%-23.28%-31.25%-16.84%814.96%62.83%-12.34%-20.42%-13.19%-24.6%
Total Current Liabilities+66.41M73.67M45.54M25.8M579.67M2.39B2.46B1.64B1.15B459.95M
Accounts Payable5.68M5.61M9.3M2.91M54.33M127.05M216.52M132.61M41.58M24.58M
Days Payables Outstanding8.72--9.33--87.55140.874.86122.82
Short-Term Debt000000324.88M002.51M
Deferred Revenue (Current)30.08M25.63M10.01M1.68M273.23M1.42B370.14M241.31M675.07M140.05M
Other Current Liabilities23.34M31.25M16.6M12.44M29.61M74.48M982.62M917.36M279.95M317.39M
Current Ratio4.33x2.76x2.62x3.77x2.15x0.90x0.69x0.70x0.98x2.13x
Quick Ratio4.10x2.58x2.36x3.77x2.15x0.90x0.68x0.67x0.97x2.10x
Cash Conversion Cycle20.96------53.9298.47-1.17-30.55
Total Non-Current Liabilities+333.44M330.55M330.37M333.18M375.6M538.11M432.81M879.28M1.03B844.32M
Long-Term Debt316.34M317.76M319.19M320.61M322.04M323.46M166.47M168.02M169.68M246.3M
Capital Lease Obligations000040.08M031.24M55.92M53.73M0
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities14.6M10.29M8.69M10.07M13.48M42.12M55.7M33.13M359.61M598.01M
Total Liabilities399.85M404.23M375.91M358.97M955.27M2.93B2.89B2.51B2.18B1.3B
Total Debt+316.34M317.76M319.19M321.87M467.98M453.99M549.78M229.08M230.42M248.81M
Net Debt171.99M211.46M249.03M243.05M-85.42M-1.06B-787.1M-339.42M-299.81M8.18M
Debt / Equity----0.75x-----
Debt / EBITDA---------0.55x
Net Debt / EBITDA---------0.02x
Interest Coverage-20.76x-12.20x-14.27x-8.86x-27.52x-79.83x-32.43x-39.30x-12.40x-
Total Equity+-5.55M-101.73M-167.94M-186.02M627.21M-351.67M-634.08M-716.93M-623.84M-127.75M
Equity Growth %-101.89%-1734.33%-65.08%-10.77%437.18%-156.07%-80.3%-13.07%12.98%79.52%
Book Value per Share-0.41-6.95-9.08-7.7210.90-4.73-8.11-7.11-4.10-0.74
Total Shareholders' Equity-5.55M-101.73M-167.94M-186.02M627.21M-351.67M-634.08M-716.93M-623.84M-127.75M
Common Stock2.72M3.24M3.85M324K714K764K868K1.41M1.62M1.65M
Retained Earnings-930M-1.11B-1.3B-1.43B-1.87B-3.62B-4.28B-4.82B-5.01B-4.57B
Treasury Stock-2.45M-2.45M-2.45M-2.58M-41.81M-85.1M-90.66M-92.27M-95.85M0
Accumulated OCI-11.81M-8.62M-11.19M-12.51M7.02M-1.35M-6.38M2.72M-22.56M2.01M
Minority Interest0000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+-255.47M-138.7M-184.82M-136.62M-42.54M322.95M-415.94M-713.97M-87.26M-244.63M
Operating CF Margin %-1663.95%-444.88%-539.04%-732.09%-190.02%163.45%-26.01%-128.32%-12.79%-21.77%
Operating CF Growth %-102.61%45.71%-33.26%26.08%68.86%859.14%-228.79%-71.65%87.78%-180.34%
Net Income-279.97M-183.77M-184.75M-132.69M-418.26M-1.74B-657.94M-545.06M-187.5M440.3M
Depreciation & Amortization8.51M9.82M8.16M5.68M4.88M12.66M29.05M41.23M48.5M27.61M
Stock-Based Compensation19.16M19.81M18.31M17.05M128.03M183.63M130.3M85.36M48.15M36.02M
Deferred Taxes374K269K-55K0000000
Other Non-Cash Items3.93M6.07M-5.35M-2.63M230.78M136.79M443.8M81.35M-44.89M-748.57M
Working Capital Changes-7.47M9.11M-21.14M-24.02M12.02M1.73B-361.15M-376.84M48.48M0
Change in Receivables2.07M01.21M-4.2M-422.69M-192.26M249.17M-274.44M354.09M61.04M
Change in Inventory-1.98M0000-600.33M-477.8M-74.46M12.91M-3.24M
Change in Payables-4.81M5.19M-6.74M0163.16M600.33M913.4M-378.81M-385.63M-322.57M
Cash from Investing+28.02M35.97M28.6M38.49M-377.78M100.15M-92.98M-58.81M-204.04M-78.27M
Capital Expenditures-18.21M-4.19M-1.37M-1.86M-54.62M-57.49M-92.98M-58.81M-14.64M-5.56M
CapEx % of Revenue118.63%13.44%4%9.95%243.98%29.09%5.82%10.57%2.15%0.49%
Acquisitions18.21M4.19M1.37M0-165.52M57.49M00192.64M0
Investments----------
Other Investing-18.2M-4.19M-1.37M18.33M0-57.49M00018.82M
Cash from Financing+279.03M64.54M102.81M98.38M984.76M461.71M324.99M4.47M260.58M27.74M
Debt Issued (Net)324.53M-37K00-96.06M-127.91M81.66M-352.35M-3.99M0
Equity Issued (Net)1000K1000K1000K1000K1000K1000K1000K1000K1000K0
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing-49.31M1.15M2.75M992K5.38M24.76M-5.9M-3.59M1.3M27.74M
Net Change in Cash51.24M-38.05M-53.47M221K566.56M879.52M-179.41M-765.03M-38.52M-289.24M
Free Cash Flow+-273.68M-142.88M-186.2M-138.48M-97.16M265.46M-508.92M-772.77M-100.32M-250.19M
FCF Margin %-1782.58%-458.32%-543.04%-742.04%-434%134.35%-31.83%-138.89%-14.71%-22.27%
FCF Growth %-89.56%47.79%-30.31%25.63%29.84%373.21%-291.71%-51.85%87.02%-149.4%
FCF per Share-20.21-9.76-10.07-5.75-1.693.57-6.51-7.67-0.66-1.45
FCF Conversion (FCF/Net Income)0.91x0.75x1.00x1.05x0.10x-0.19x0.63x1.31x0.47x-0.56x
Interest Paid00012.19M13.71M19.43M18.04M17.35M17.57M0
Taxes Paid0000012.61M17.98M190K949K0

Key Ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-195.01%----189.6%-1265.72%----
Return on Invested Capital (ROIC)-110.17%-93.27%-136.71%-130.94%-104.38%-----
Gross Margin-1449.79%100%100%-510.02%100%100%43.55%38.21%70.28%93.5%
Net Margin-1823.53%-589.46%-538.81%-697.15%-1868.23%-882.55%-41.15%-97.97%-27.49%39.19%
Debt / Equity----0.75x-----
Interest Coverage-20.76x-12.20x-14.27x-8.86x-27.52x-79.83x-32.43x-39.30x-12.40x-
FCF Conversion0.91x0.75x1.00x1.05x0.10x-0.19x0.63x1.31x0.47x-0.56x
Revenue Growth-57.65%103.06%9.98%-45.57%19.97%782.53%709.26%-65.2%22.61%64.69%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.